Core Viewpoint - Tianjin Tianshili (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the dual targets, blocking the tumor cell cycle and inducing apoptosis in tumor cells [1] - TSL2109 aims to synergistically kill tumor cells through its dual-target mechanism [1]

Core Viewpoint - Tianshili (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Diyi"), has received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the two targets, blocking the tumor cell cycle and inducing tumor cell apoptosis [1] - TSL2109 aims to synergistically kill tumor cells through its dual-target mechanism [1]

Core Viewpoint - The announcement indicates that Tianjin Tasly Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of TSL2109 capsules, a new dual-target small molecule inhibitor for advanced solid tumors [1] Company Summary - Jiangsu Diyi, a wholly-owned subsidiary of Tianjin Tasly, is responsible for the development of TSL2109 capsules in collaboration with China Pharmaceutical University [1] - The total investment in the research and development of TSL2109 capsules has reached RMB 24.6251 million [1] Industry Summary - The approval for clinical trials highlights the ongoing innovation in the pharmaceutical industry, particularly in the development of new cancer therapies [1] - The development process of new drugs is characterized by uncertainty, and future market competition dynamics are expected to change [1]